MarketPeel
MA

Maricel Apuli

BBIO
CHIEF ACCOUNTING OFFICER · BRIDGEBIO PHARMA, INC. · CIK 0002058197
FILING MIX · LIFETIME13%/87%
BUYS
2
SELLS
14
TOTAL VALUE
$2.60M
COMPANIES
1
ACTIVE SINCE
Mar 2025
HOLDINGS NOW
122,687
AVG SELL PX
$63.88
TRADE KIND
SHOWING 16 / 16
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 11 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Maricel Apuli, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%-2.81%+0.41%-3.22%-3.96%
14d6+50.00%-2.89%+0.85%-3.74%-1.74%
30d6+50.00%-0.02%-0.71%+1.44%-0.83%
60d6+33.33%+5.27%+4.24%+1.03%-0.36%
90d6+33.33%+8.99%+5.94%+4.81%+11.03%
180d6(1 pending)+20.00%+32.18%+12.53%+19.65%+9.15%
1y6(4 pending)+0.00%+78.09%+24.36%+53.74%+53.74%
2y6(6 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BBIO · 122,687 shares · as of Aug 16, 2026
037,16674,333111,499148,6652026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
2026
2026
FLOW · 2 buys / 14 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,714$79.86$376.5K122,687Aug 16, 2026Aug 18, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
2,000$80.06$160.1K127,401Jul 30, 2026Aug 3, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,714$66.13$311.7K129,401May 16, 2026May 19, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
2,000$71.58$143.2K134,115Apr 30, 2026May 4, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
14,170136,115Mar 18, 2026Mar 20, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
2,000$66.00$132.0K121,945Feb 26, 2026Feb 27, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
510$74.31$37.9K123,945Feb 17, 2026Feb 18, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,349$75.25$327.3K124,455Feb 16, 2026Feb 18, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
2,003$75.15$150.5K128,294Dec 12, 2025Dec 16, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
2,000$74.26$148.5K130,297Dec 8, 2025Dec 10, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,781$66.39$317.4K132,297Nov 16, 2025Nov 18, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,781$51.32$245.4K137,078Aug 16, 2025Aug 19, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
1,000$45.44$45.4K141,859Aug 7, 2025Aug 11, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
4,780$33.84$161.8K142,859May 16, 2025May 20, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
Chief Accounting Officer
1,026$38.51$39.5K147,639May 2, 2025May 6, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
23,660148,665Mar 19, 2025Mar 21, 2025View →
Other insiders · BBIO
Loading peer insiders…
About this filer
CIK 0002058197
ROLE
Chief Accounting Officer
PRIMARY
BBIO
COMPANIES
1
ACTIVE SINCE
Mar 2025
MARKETPEEL · /INSIDER/0002058197DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback